279 related articles for article (PubMed ID: 33023002)
21. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
[TBL] [Abstract][Full Text] [Related]
22. Transplantation.
Zain J
Cancer Treat Res; 2019; 176():269-287. PubMed ID: 30596223
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
[TBL] [Abstract][Full Text] [Related]
24. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma.
Cudillo L; Cerretti R; Picardi A; Mariotti B; De Angelis G; Cantonetti M; Postorino M; Ceresoli E; De Santis G; Nasso D; Pisani F; Scala E; Di Piazza F; Lanti A;
Ann Hematol; 2018 Jun; 97(6):1041-1048. PubMed ID: 29442161
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas.
Paralkar VR; Nasta SD; Morrissey K; Smith J; Vassilev P; Martin ME; Goldstein SC; Loren A; Rook AH; Kim EJ; Porter DL
Bone Marrow Transplant; 2012 Jul; 47(7):940-5. PubMed ID: 22020023
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies for cutaneous T-cell lymphomas.
Kaplan JB; Guitart J; Giles FJ
Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
Welborn M; Duvic M
Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.
Gibson JF; Alpdogan O; Subtil A; Girardi M; Wilson LD; Roberts K; Foss F
J Am Acad Dermatol; 2015 Jun; 72(6):1010-5.e5. PubMed ID: 25981001
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Bertz H; Illerhaus G; Veelken H; Finke J
Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
36. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.
Guitart J; Wickless SC; Oyama Y; Kuzel TM; Rosen ST; Traynor A; Burt R
Arch Dermatol; 2002 Oct; 138(10):1359-65. PubMed ID: 12374543
[TBL] [Abstract][Full Text] [Related]
37. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.
Schlaak M; Pickenhain J; Theurich S; Skoetz N; von Bergwelt-Baildon M; Kurschat P
Cochrane Database Syst Rev; 2012 Jan; 1():CD008908. PubMed ID: 22258991
[TBL] [Abstract][Full Text] [Related]
40. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.
Giordano A; Pagano L
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022029. PubMed ID: 35444765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
